Switching Trial of Adjuvant Tamoxifen with an Aromatase Inhibitor in Postmenopausal Patients with Breast Cancer
- 1 September 2004
- journal article
- review article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 5, S13-S17
- https://doi.org/10.3816/cbc.2004.s.009
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancerCancer, 2003
- Randomized Trial of 2 Versus 5 Years of Adjuvant Tamoxifen for Women Aged 50 Years or Older With Early Breast Cancer: Italian Interdisciplinary Group for Cancer Evaluation Study of Adjuvant Treatment in Breast Cancer 01Journal of Clinical Oncology, 2003
- American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor–Positive Breast Cancer: Status Report 2002Journal of Clinical Oncology, 2002
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- Sequential Tamoxifen and Aminoglutethimide Versus Tamoxifen Alone in the Adjuvant Treatment of Postmenopausal Breast Cancer Patients: Results of an Italian Cooperative StudyJournal of Clinical Oncology, 2001
- Five Versus More Than Five Years of Tamoxifen for Lymph Node-Negative Breast Cancer: Updated Findings From the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized TrialJNCI Journal of the National Cancer Institute, 2001
- Aromatase Inhibitors in the Treatment and Prevention of Breast CancerJournal of Clinical Oncology, 2001
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Postchemotherapy Adjuvant Tamoxifen Therapy Beyond Five Years in Patients With Lymph Node-Positive Breast CancerJNCI Journal of the National Cancer Institute, 1996
- Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancerBritish Journal of Cancer, 1996